Navigation Links
Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration to Accelerate Personalized Medicine Approaches for Multiple Myeloma
Date:12/14/2011

NORWALK, Conn. and SOUTH SAN FRANCISCO, Calif., Dec. 14, 2011 /PRNewswire/ -- The Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the start of a multi-year collaboration in support of the comprehensive research initiative in personalized medicine sponsored by the MMRF. The MMRF's Personalized Medicine Initiative, the largest research effort ever undertaken against this incurable disease, is designed to enable the molecular characterization of patients with multiple myeloma and advance the development of new, targeted treatments for the disease.

As a charter member of a growing pre-competitive consortium which includes academic, industry and non-profit members, Onyx, which has a focus in multiple myeloma, will provide scientific and financial support for this comprehensive research initiative. The pre-competitive component of the collaboration gives the consortium equal access to data generated for a set period of time before the data is released in the public domain.

"We look forward to working closely with Onyx to gain a much better understanding of how this disease develops and progresses, and to bring the entire R&D ecosystem together to greatly accelerate the development of new treatments, and ultimately, a cure," said Kathy Giusti, founder and CEO of the MMRF and Multiple Myeloma Research Consortium, and a multiple myeloma patient. "Onyx is an invaluable partner who shares our passion for rapidly translating new insights into breakthrough therapies to bring us closer to a cure. We look forward to working together in this critical initiative."

The MMRF announced earlier this year that enrollment has begun in its CoMMpass(SM) Study (relating Clinical Outcomes in Multiple Myeloma to Personal AsseSSment of genetic profile), the cornerstone of the multiple myeloma personalized medicine research e
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Multiple Myeloma Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... N.Y. , July 2, 2015  Before you head ... ahead so you can stay safe and healthy. Take steps ... #summersafety. Infographic http://nyackhospital.org/summersafety Protect Your Skin ... from the sun can increase your risk of skin cancer. ... shade as much as possible, especially during midday hours. Wear ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ) has announced the addition ... Application - Forecast to 2020" report to their offering. ... Billion in 2020 from an estimated $7.1 Billion in 2015, growing ... by North America , followed by ... the World (RoW). The cancer diagnostics market in Asia ...
(Date:7/2/2015)... , July 2, 2015   Decision Resources ... retinal specialists identify less frequent dosing as the ... due to the burden on both patients and ... growth factor (VEGF) injections, which are the current ... abicipar pegol, which is in development for dosing ...
Breaking Medicine Technology:First Aid Summer Survival Tips from Nyack Hospital 2First Aid Summer Survival Tips from Nyack Hospital 3Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3
... BETHLEHEM, Pa., May 15, 2012  MedClean Technologies, Inc. (OTC Bulletin ... ended December 31, 2011. 2011 Year-end Operational ... 91% to $1,717,721 compared to $896,993 for 2010.  , ... gross profit of $470,295 for 2010. , Net cash ...
... May 15, 2012  Coloplast North America, a provider of ... has announced a corporate sponsorship of Michael Johnson, formula ... competing this year in The Cooper Tires USF2000 Championship ... to Indy, an open-wheeled development program for drivers seeking ...
Cached Medicine Technology:MedClean Technologies Announces 2011 Results 2MedClean Technologies Announces 2011 Results 3MedClean Technologies Announces 2011 Results 4MedClean Technologies Announces 2011 Results 5First Paralyzed Formula Race Car Driver's "Road to Indy" Sponsored By Coloplast 2
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Renowned ... the dates for the 2016 Dallas Rhinoplasty Symposium . To be held from ... the meeting will be held at the Westin Galleria Dallas. , Designed to take ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... to healthcare providers, has been retained to lead a national chief nursing ... the top-ranked executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/3/2015)... CT (PRWEB) , ... July 03, 2015 , ... Smoothies ... home is a good blender and easily accessible, quality ingredients. Aurora Natural is proud ... smoothie for an added boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Jennifer Renee ... First Choice Emergency Room , the largest network of independent freestanding emergency rooms in ... facility medical director of our Sienna Plantation facility,” said Executive Medical Director of First ...
(Date:7/3/2015)... ... 03, 2015 , ... " Selfie on a Stick ” was featured on ... technology products available to consumers. Amanda Forstrom, a technology expert and special reporter for ... for documenting memories. , Almost every smartphone has an incredibly powerful camera built into ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Learn How to Take Selfies like Kendall Jenner 2
... to create a $60 billion company, will it be a good deal or ... a bad deal for both companies. , ... Oxford, UK (PRWEB) January 23, 2009 -- ... be a good deal or a bad deal? Fintan Walton, PhD, CEO of ...
... HOLLYWOOD, Calif., Jan. 23 IPC The Hospitalist Company, ... hospitalist physician group practice company, today announced that it ... Angeles Venture Association (LAVA).LAVA Executive Director Leonard Lanzi said, ... companies, such as IPC. In this environment, anyone who ...
... 700 top Australian and international scientists will gather in ... Society (ANS) meeting. It marks a homecoming for the ... Canberra in 1980, with substantial input from ANU. , ... four plenary sessions will be made by neuroscientists throughout ...
... 23, 2009 Elsevier, the world,s leading publisher of ... today that over 600 Medical, Veterinary Medicine, and Health ... eBook Collections in April 2009 on ScienceDirect, its online ... science books are published under the imprints W.B. Saunders, ...
... Seal Fits Your Smile to Fit Your Life -CINCINNATI, ... its most advanced innovation in teeth whitening technology: New ... molds the strip to users, teeth, allowing them to ... anywhere, anytime. The secure fit comes off clean ...
... Year 2008 Revenue of Approximately $250 MillionAnnounces Full ... $350 MillionSAN DIEGO, Jan. 23 NuVasive, Inc. ... company focused on developing products for minimally disruptive ... unaudited financial results for the full year ended ...
Cached Medicine News:Health News:Pfizer - Wyeth: Good Deal – Bad Deal? 2Health News:IPC The Hospitalist Company Receives 'Best IPO' Award from Los Angeles Venture Association 2Health News:IPC The Hospitalist Company Receives 'Best IPO' Award from Los Angeles Venture Association 3Health News:The world's best brains descend on Canberra 2Health News:Elsevier to launch over 600 health science e-Book titles on ScienceDirect 2Health News:Crest Whitestrips Introduces a Revolutionary New Teeth Whitening Technology 2Health News:Crest Whitestrips Introduces a Revolutionary New Teeth Whitening Technology 3Health News:NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results 2Health News:NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results 3Health News:NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results 4
... Magnetic stimulation is a non-invasive and painless ... nervous system. Cadwell Laboratories manufactures two magnetic ... Speed Magnetic Stimulator (HSMS). The Hight Speed ... rates up to 25 Hz at full ...
... most advanced defibrillator monitor ever made, with all ... (5kg). Half the weight and a third the ... M Series has everything you need for cardiac ... ECG with advanced monitoring, built-in AC or DC ...
... MOBEE headboxes are ... Xltek's line of portable ... with a robust new ... latest software, XLTEK's standard ...
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: